• Ayşe Demirci, Cemil Bilir, Emre Cakir, Burcu Gulbagci, Ilhan Hacibekiroglu, and Ceyhun Varim.
• Department of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey.
• J Coll Physicians Surg Pak. 2021 Jan 1; 31 (1): S66S70S66-S70.

ObjectiveTo evaluate the mortality rates in patients receiving anticancer therapy in the coronavirus disease-19 (COVID-19) pandemic period.Study DesignDescriptive study.Place And Duration Of StudyDepartment of Medical Oncology, Sakarya University Training and Research Hospital, Sakarya, Turkey, from December 2017 to May 2020.MethodologyOnly patients who received chemotherapy and immunotherapy were selected and enrolled in the study. All patients (n=3,204) were divided into three groups, namely the first group (1st December 2017-31st May 2018, n=918), second group (1st December 2018-31st May 2019, n=1,147), and the pandemic period group (PPG) (1st December 2019-31st May 2020, n=1,139), according to the period during which they received anticancer treatment. The clinical and demographic characteristics and mortality rates of these three groups of patients were compared.ResultsThe median age of the total of 3,204 patients was 61 (53-69). In this study, 51.1% (n=1,636) were females and 48.9% were males. The mortality rates were 13.5% (n=124) in the first group, 13.4% (n=154) in the second group, and 13.0% (n=148) in the PPG, respectively. Overall mortality rates did not differ among patients with cancer in the three different six-month periods analysed (p = 0.931).ConclusionThere was no unexpected increased in mortality rate among patients undergoing cancer therapy during the COVID-19 pandemic as compared to the previous years of the same timeline. No increase in monthly mortality rates among patients receiving anti-cancer treatment were demonstrated during the pandemic period.

23 keywords...

hide…